"para-Aminobenzoates" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
| Descriptor ID |
D062366
|
| MeSH Number(s) |
D02.241.223.100.050.500 D02.455.426.559.389.127.020.937
|
| Concept/Terms |
para-Aminobenzoates- para-Aminobenzoates
- para Aminobenzoates
- 4-Aminobenzoates
- 4 Aminobenzoates
- p-Aminobenzoates
- p Aminobenzoates
|
Below are MeSH descriptors whose meaning is more general than "para-Aminobenzoates".
Below are MeSH descriptors whose meaning is more specific than "para-Aminobenzoates".
This graph shows the total number of publications written about "para-Aminobenzoates" by people in this website by year, and whether "para-Aminobenzoates" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "para-Aminobenzoates" by people in Profiles.
-
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood Adv. 2022 07 26; 6(14):4147-4156.
-
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ? idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncol. 2020 May; 16(13):807-815.
-
Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. Nat Commun. 2019 09 25; 10(1):4363.
-
Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell. 2017 Dec 11; 32(6):748-760.e6.
-
p53 Nongenotoxic Activation and mTORC1 Inhibition Lead to Effective Combination for Neuroblastoma Therapy. Clin Cancer Res. 2017 Nov 01; 23(21):6629-6639.
-
Development and structural analysis of adenosine site binding tankyrase inhibitors. Bioorg Med Chem Lett. 2016 Jan 15; 26(2):328-333.
-
Reactivation of p53 via MDM2 inhibition. Cell Death Dis. 2015 Oct 22; 6:e1936.
-
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorg Med Chem. 2014 Aug 01; 22(15):4001-9.
-
Tongue entrapment in an aluminum juice can. Pediatr Emerg Care. 2004 Apr; 20(4):242-3.
-
Controlled comparison of topical anesthetic agents in flexible upper gastrointestinal endoscopy. Gastrointest Endosc. 1985 Aug; 31(4):255-8.